



Drug resistance and tolerance in fungi

Judith Berman¹ and Damian J. Krysan²

Abstract | Systemic fungal infections pose a serious clinical problem. Treatment options are limited, and antifungal drug resistance is increasing. In addition, a substantial proportion of patients do not respond to therapy despite being infected with fungi that are susceptible to the drug. The discordance between overall treatment outcome and low levels of clinical resistance may be attributable to antifungal drug tolerance. In this Review, we define and distinguish resistance and tolerance and discuss the current understanding of the molecular, genetic and physiological mechanisms that contribute to those phenomena. Distinguishing tolerance from resistance might provide important insights into the reasons for treatment failure in some settings.

Candidaemia

Candidaemia is a candidal infection of the blood stream.

Drug-resistant fungal infections are emerging as an important clinical problem^{1,2}. This is mainly owing to an increase in patients at risk for invasive fungal infections from complex surgical procedures, immune suppression or reduced immune function³. Patients who develop invasive fungal infections in the setting of other serious medical conditions frequently have increased mortality rates compared with uninfected patients. For example, the 90-day mortality rate for recipients of solid organ transplants who develop candidaemia is between 22% and 44%, depending on the *Candida* species⁴.

The recent emergence of fungi that are resistant to more than one class of antifungal drug is a serious concern. Currently, only three primary classes of agents are used to treat invasive fungal infections⁵: polyenes (for example, amphotericin B), azoles (for example, fluconazole) and echinocandins (for example, caspofungin) (TABLE 1). Thus, one antifungal drug class becoming ineffective in treating a fungal infection due to resistance reduces the therapeutic options by at least 33% and frequently by 50% because azoles and echinocandins are not active against all fungi. By comparison, six distinct classes of antibiotics are currently available to treat methicillin-resistant *Staphylococcus aureus*, an important and widespread drug-resistant bacterium⁶. Thus, the loss of one antifungal drug through resistance has a major impact on patient care.

Resistance to all classes of antifungal drugs has been characterized in most fungal species that infect humans. In general, antifungal resistance has two operational definitions. First, in the clinical microbiology laboratory, fungal strains are classified using standardized assays (BOX 1) to compare the minimum inhibitory concentration (MIC) to the clinical breakpoints for that drug, which take into account in vivo aspects of drug efficacy. Resistant strains have MICs above the breakpoint and are more likely to cause a therapeutic failure

than susceptible strains with MICs below the breakpoint. Second, in research laboratories studying the mechanisms of antifungal activity, in vitro resistance refers to a strain that is less susceptible (that is, has a higher MIC) to a drug than a control or reference strain and will be termed resistant in this Review.

Although relatively low levels of resistance for most *Candida* species have been described, the outcomes for candidaemia remain poor, as high levels of mortality (15–50%) have been associated with candida infections⁷. For example, the rate of fluconazole and echinocandin resistance in *Candida albicans*, the most prevalent *Candida* species, is generally less than 1% (REF.⁷), yet existing therapies often fail to treat infections caused by susceptible *Candida* isolates. This has been attributed to non-mycologic causes, such as host factors, immune status and/or pharmacologic issues⁸. However, specific interactions between the drug and the fungus, aside from the MIC, may affect therapeutic responses as well. Specifically, the discordance between overall treatment outcome and low levels of clinical resistance may be attributable to antifungal drug tolerance.

The terms antifungal drug resistance and tolerance are frequently used as synonyms in the literature. However, a more nuanced understanding of the fungal response to drugs may help explain the poor outcomes for infections caused by apparently susceptible isolates (that is, isolates that have a susceptible MIC at 24 h, the standard end point for MIC measurements for *Candida* species). In this Review, we define antifungal tolerance as the ability of a drug-susceptible fungal strain to grow in the presence of an antifungal drug at concentrations above the MIC⁹. Subpopulations of tolerant cells grow slowly in drug concentrations above the MIC, which is usually visually evident after time periods longer than the standard 24 h for MIC measurements. In the same isogenic population, a second subpopulation of cells

¹School of Molecular Cell Biology & Biotechnology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Israel.

²Department of Pediatrics and Microbiology/Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.

✉e-mail: berma003@umn.edu

<https://doi.org/10.1038/s41579-019-0322-2>

Table 1 | Mechanisms of resistance to clinically relevant classes of antifungal drugs

Drug class	Examples of clinically used drugs	Mechanism of action	Target	Mechanism of acquired resistance	Species with intrinsic or high rates of resistance
Azole	Fluconazole, voriconazole, posaconazole	Inhibition of ergosterol biosynthesis	Lanosterol 14 α -demethylase (Erg11 or Cyp51 in other organisms)	Increased efflux pump activity, <i>ERG11</i> mutations, <i>CYP51</i> promoter mutations	<i>Candida glabrata</i> , <i>Candida krusei</i> , <i>Candida auris</i>
Echinocandins	Caspofungin, micafungin, anidulafungin	Inhibition of 1,3- β -glucan synthase	1,3- β -glucan synthase (Fks)	Mutations in hotspot regions of <i>FKS</i> mutations	<i>Cryptococcus</i> spp., <i>Fusarium</i> spp.
Polyene	Amphotericin B	Ergosterol sequestration	Ergosterol	Decreased membrane ergosterol, <i>ERG</i> mutations	<i>C. auris</i> , <i>Aspergillus terreus</i>

Susceptibility

Sensitivity to a drug, arresting growth (static drugs) and/or killing cells (cidal drugs).

Fraction of growth

A measure of tolerance based on assays performed on a liquid medium. Measured at 48 h, the growth within the zone of inhibition (and thus above the minimum inhibitory concentration) is estimated as a proportion of total growth possible outside the zone of inhibition.

Supra-MIC growth

(SMG). A measure of tolerance based on assays performed in a liquid medium. Growth at concentrations above the minimum inhibitory concentration is estimated as a proportion of the total growth without a drug. SMG provides a quantitative measure of growth similar to some measures of trailing growth.

Phenotypic heterogeneity

The expression of different phenotypes in different cells within an isogenic population of cells. For example, some fungal cells grow whereas other sister cells do not grow (or grow too slowly to be detected) in the presence of an antifungal drug.

Fungistatic drugs

Drugs that inhibit growth but do not necessarily kill a majority of the cell population at concentrations at or above the minimum inhibitory concentration.

Heteroresistance

A clinical term for isolates that contain small subpopulations of cells (generally <1%) that have the ability to grow at drug concentrations that are at least 8 \times the minimum inhibitory concentration for the vast majority of susceptible cells in the population.

does not grow in the drug or its extremely slow growth is not detectable following 48 h in the drug. We posit that antifungal tolerance is a property of pathogenic fungi that can be distinguished from resistance using the same in vitro assay that can quantify both susceptibility (measured as MIC at 24 h) and growth properties at 48 h, such as the fraction of growth or supra-MIC growth (SMG) (BOX 1). We further suggest that the question of whether tolerance may explain some of the discordance between clinical outcome and clinical MIC measurements is worthy of larger-scale clinical studies.

A recent quantitative study⁹ identified four characteristics of fluconazole-tolerant cells across a set of seven diverse *C. albicans* isolates. First, tolerance of an isolate is relatively reproducible, with differences in tolerance levels between isolates presumed to be affected by intrinsic genetic differences between those isolates (FIG. 1a). Second, within a given isolate, tolerant cells (those that do grow slowly in the presence of the drug, whereas the remaining cells do not grow) represent a subpopulation (generally 5–90% of the cells, depending on the isolate) (FIG. 1b). Third, tolerance is largely independent of the drug concentration (BOX 1). Fourth, the time required for cells to appear as visible colonies on a Petri plate containing the drug is shorter for isolates with high tolerance levels than for isolates with lower tolerance levels (FIG. 1c). Thus, drug tolerance is a manifestation of phenotypic heterogeneity intrinsic to a given fungal isolate.

Although the definition of in vitro resistance is similar for bacteria and fungi, some aspects of antifungal tolerance differ from antibacterial tolerance. Tolerant bacterial and fungal isolates have MICs in the susceptible range, but tolerant bacteria are characterized by a longer minimum duration to killing than susceptible isolates¹⁰, based on responses to bactericidal drugs^{10–12}. By contrast, antifungal tolerance is most evident with fungistatic drugs, and thus measuring cell death is less relevant. Furthermore, higher tolerance in bacterial isolates is associated with a longer lag phase length, whereas fungal isolates with higher tolerance levels have a shorter lag phase length (measured as the time required for colonies to become visible¹³) relative to those with lower tolerance levels⁹.

Studies are beginning to provide evidence that tolerance is associated with multiple genetic components that differ between isolates. These genetic components affect

the ability of isogenic cells within a single isolate to respond physiologically or metabolically (to environmental or nutritional signals). The genetic make up of an individual isolate may also affect the degree of variability between the responses of different isogenic cells in the population. We know that chaperone activity, the availability of calcium and iron utilization and membrane proteins that regulate drug uptake and/or efflux, along with components of several central stress response pathways, such as protein kinase C/RAS and MAP kinase cascades, are required for the ability to grow slowly (and to grow at all) in the drug. However, the degree to which these pathways affect differences between genetically different isolates and the degree to which they are critical at the level of cell-to-cell differences remain to be determined (FIG. 1e).

Growth of subpopulations of susceptible fungal isolates in the presence of drugs at concentrations above the MIC can be due to tolerance, heteroresistance or persistence (see BOX 2), depending on the drug, the organism and the size of the subpopulation. Whereas tolerance is generally owed to substantial subpopulations of cells (5–90%) that grow in the drug, antifungal heteroresistance or persistence involve rare cells (generally <<1%) that transiently survive high concentrations of antifungal drugs¹⁴. The distinctions between susceptibility, resistance, tolerance and heteroresistance, all mechanisms that involve phenotypic heterogeneity, are discussed in BOX 2.

Trailing growth is a term used primarily in the clinical context and has been defined as reduced but persistent visible growth of *Candida* spp. at fluconazole concentrations above the MIC¹⁵. Trailing growth is often estimated as the percentage of growth at different drug concentrations relative to growth in the absence of the drug¹⁶, a measure similar to the SMG parameter used to measure tolerance (FIG. 1b). Like tolerance, trailing growth is sensitive to growth conditions^{17–19}; the degree of sensitivity to these conditions differs for different clinical isolates^{9,20} and leads to considerable laboratory-to-laboratory variation in the estimation of trailing growth. Noteworthy, tolerant or trailing cells, when retested, have a similar MIC and a similar slow/partial growth in the presence of drugs at concentrations above the MIC (FIG. 1a). Thus, we use the term ‘trailing’ for describing studies that used that term, with the assumption

Box 1 | Measuring antifungal resistance and tolerance

Standard assays of antifungal resistance


Clinical laboratory definitions of resistance are based on assays performed according to stringent criteria. Resistance is measured and quantified using three types of assays: disc diffusion assays (see the figure, part a), broth microdilution assays (see the figure, part b) or E-test strips (see the figure, part c). These tests are usually performed after 24 h of growth. Disc diffusion assays are performed by spreading fungal cells on agar medium and then placing a filter disc containing a standard concentration of the drug on the plate; fungal growth produces a lawn outside the zone of inhibition (see the figure, part a). Images of the plates are analysed using diskImageR³⁶, a software program that averages pixel intensity along 72 radii emanating from the disc and estimates the average pixel intensity corresponding to the cell density as a function of distance from the disc. The level of susceptibility is measured as the average radius (RAD), which corresponds to the point where growth is inhibited by 20%, 50% or 80% (RAD₂₀, RAD₅₀ or RAD₈₀, respectively), relative to the maximum radius (see the figure, part a bottom panels). The minimum inhibitory concentration (MIC) is inversely correlated with the RAD. Shown are disc diffusion assays for two isolates with similar MIC levels and different tolerance levels, as determined from the degree of growth within the region of growth inhibition detected visually on the plates and calculated using diskImageR (as described below).

Broth microdilution assays (see the figure, part b) are performed by diluting a standard number of cells in microtitre wells containing the drug in increasing concentrations (usually twofold increments) and propagating them. The lowest concentration that inhibits growth by 50% (MIC₅₀) or more is generally considered the MIC (indicated by the vertical line and boxed wells); the Clinical and Laboratory Standards Institute (CLSI) suggests visual reading of the plates, and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommends measuring optical density. E-test strips (see the figure, part c) contain a gradient of drug and include markings that correspond to the drug concentration. The MIC is determined from the position of the edge of the zone of inhibition (indicated by the arrow) after 24 h of growth.


Clinical breakpoints refer to MIC values above which isolates are considered resistant. Specific clinical breakpoints for fluconazole (FLC), voriconazole and the echinocandins have been established for *Candida albicans*, *Candida glabrata*, *Candida parapsilosis*, *Candida krusei*, *Candida tropicalis* and *Candida guilliermondii*. No amphotericin B breakpoints are available for any organisms. Based on the clinical breakpoints, interpretive guidelines have been established by the CLSI or EUCAST for these organisms and classify strains as sensitive, resistant or intermediate.

Measuring antifungal tolerance

Tolerance is quantified using either disc diffusion assays or broth microdilution assays, generally after 48 h of growth. In disc diffusion assays, diskImageR calculates the fraction of growth (FoG) inside the zone of inhibition for a given RAD (usually at 20% or 50% inhibition) as the pixel intensity in the area under the curve (see the figure, part a pink region) relative to the maximum area possible (at the chosen RAD level (illustrated for RAD₂₀ as the dashed rectangle, see the figure, part a)). Strains with similar levels of susceptibility (determined as MIC/RAD) often exhibit different levels of tolerance and are illustrated in the figure. Note that tolerant growth is often similar in density, measured as a similar pixel intensity, over some distance from the disc. Broth microdilution assays analysed at 48 h also provide a tolerance metric, termed supra-MIC growth (SMG)¹⁴. SMG is quantified as the average growth per well (measured as optical density), for all drug concentrations above the MIC, normalized to growth in the absence of the drug (see the figure, part c). E-test strip assays provide a visual approximation of tolerance as the proportion of growth within the zone of inhibition relative to growth outside it (see the figure, part c). Solid media assays (see the figure, parts a and c) enable the visualization of subpopulation growth, evident as individual colonies, as well as the effect of drug concentration. By contrast, liquid assays do not distinguish between very slow growth of all cells in the population and slow growth of a subpopulation of cells.



Box figure parts a and b are adapted from REF⁹, CC BY 4.0 (<https://creativecommons.org/licenses/by/4.0/>). Image in Box figure part c courtesy of Mohamed Hajooj, Tel-Aviv University.



◀ Fig. 1 | **Phenotypic characteristics and pathways required for antifungal tolerance.**

Tolerance is a phenotypic property of a given isolate that differs between different clinical isolates. The subpopulation of cells in the tolerant state (characterized by slow growth within the zone of inhibition in disc diffusion assays (BOX 1)) is isogenic to cells in the non-tolerant state (the whole population of cells that grow outside the zone of inhibition). **a** | A disc diffusion assay with a single drug disc in the centre of a Petri plate is shown; the zone of inhibition border is indicated in yellow (top panel). When cells from this plate are spread on new plates with the same amount of drug, similar patterns of growth are observed for tolerant cells taken from within the zone of inhibition (bottom left) and non-tolerant cells taken from outside the zone of inhibition (between the yellow and cyan circles), indicating that cells retain a similar potential to give rise to both types of subpopulations (tolerant and non-tolerant) in similar ratios. The radius of the zone of inhibition, used to determine the minimum inhibitory concentration (MIC), and the fraction of growth (FoG), used to measure tolerance (BOX 1), are similar in all three plates (not indicated). Similar results are also obtained with broth microdilution assays (not shown). **b** | Tolerance (measured as FoG at 20% drug inhibition (FoG₂₀) (see BOX 1)) correlates with the proportion of colonies that appear at fluconazole (FLC) concentrations above the MIC (relative to total colonies growing in the absence of drug). Different strains are represented by different coloured dots. **c** | The time required for cells to appear as visible colonies on a Petri plate containing the drug (time of colony appearance (ToA)) is shorter for isolates with high tolerance levels than for isolates with lower tolerance levels. Shown is a comparison between three clinical isolates that exhibit different levels of tolerance (indicated by the different FoG levels). The average difference between the ToA on plates containing an inhibitory drug concentration (red lines) and the ToA on plates without the drug (blue lines), Δ ToA, inversely correlates with the level of tolerance (FoG levels). The growth rates of visible colonies and the final colony sizes are largely independent of tolerance levels. **d** | Strains with low and increasing levels of tolerance are composed of cells with different amounts of intracellular azole drug. Shown are four susceptible strains, with increasing levels of tolerance (from left to right), and one resistant strain (far right). Among the susceptible strains, the proportion of cells with high amounts of intracellular drug decreases with increasing tolerance levels. The proportion of cells with high (red), intermediate (light red) and low (pink) intracellular drug concentrations of a fluorescent azole antifungal (Cy5-azole) drug differ from each other by an order of magnitude, as measured by flow cytometry⁹. The resistant strain has a much larger proportion of cells with low intracellular drug concentration. **e** | Studies using mutants and inhibitors reveal general stress pathways that affect tolerance. Proteins and pathways implicated in tolerance (green) and compounds that inhibit those pathways and also inhibit tolerance (blue) seem to converge on the cellular processes involved in membrane integrity and/or cell wall function. Some of the inhibitors affect more than one gene or pathway. For example, heat shock protein 90 (Hsp90) inhibits calcineurin, which in turn activates Crz1, a transcription factor required for membrane integrity as well as for tolerance^{26,27,127}. Fluphenazine, an adjuvant drug that inhibits tolerance and renders FLC cidal⁹, is an inhibitor of both protein kinase C, which has been implicated in FLC tolerance²², and calmodulin, which is a regulator of calcineurin activity and, ultimately, membrane and cell wall integrity¹²⁸. This implies that tolerance relies on one or both of these central regulators for cell viability in the presence of FLC. It is noteworthy that published studies investigating drug responses are difficult to interpret because the terms resistance and tolerance have been used interchangeably. Nonetheless, most published data are consistent with the notion that the regulation of both membrane integrity and cell wall function is important for tolerance. CFU, colony-forming units; TOR, target of rapamycin. Parts **a–d** are adapted from REF.⁹, CC BY 4.0 (<https://creativecommons.org/licenses/by/4.0/>). Part **e** is based on data from REF.⁹ together with many other studies (reviewed elsewhere¹²⁹).

antifungal responses of biofilms and paradoxical growth are discussed in BOX 3.

In this Review, we explore the molecular mechanisms that contribute to antifungal drug resistance, with a focus on *Candida* spp., the most common cause of fungal infections in humans⁷. We then contrast the concepts of resistance and antifungal drug tolerance and present our current understanding of the mechanisms and phenotypes associated with tolerance. We assert that distinguishing tolerance from resistance may provide important insights into the reasons for treatment failure in some settings and the eventual development of resistance. Finally, we also discuss therapeutic approaches to reduce and/or overcome antifungal drug resistance and tolerance.

Antifungal drug resistance

Measuring and defining resistance. Resistance, the ability to grow in levels of drug that inhibit susceptible isolates, is measured clinically as an increase in the MIC of a given antifungal drug when tested according to approved methods standardized by governing bodies, such as the Clinical and Laboratory Standards Institute (CLSI)²³ or the European Committee on Antimicrobial Susceptibility Testing (EUCAST)²⁴. Clinical breakpoints provide guidance regarding the likelihood that a given isolate will respond to therapy. Epidemiological cut-off values use MICs to identify isolates with acquired resistance, usually via mutations²⁵.

It is important to distinguish clinical laboratory definitions of resistance from less-stringent criteria frequently used in the literature. Specifically, many published reports refer to resistance as an increase in the MIC relative to a reference strain, particularly in the setting of work focused on elucidating the mechanisms of resistance. In addition, non-standard assays are frequently used to measure antifungal activity but do not generate an MIC value. For example, serial dilution agar plating assays frequently compare the susceptibility of one isolate or a mutant with its appropriate reference strain; isolates and mutants that grow better than the reference strain in these assays are often referred to as resistant. Further effects could be due to tolerance or trailing, rather than resistance^{9,26–29}, because the MIC was not altered at 24 h. Instead, increased growth in the presence of the drug (relative to a reference strain) was usually detected at 48 h. Thus, when evaluating the literature, it is prudent to note the author's definition of resistance and the conditions used to measure the phenomenon.

Mechanisms of drug resistance in fungi. Although resistance is emerging in non-*Candida* species, such as *Aspergillus* spp.³⁰, the general molecular mechanisms of resistance are conserved; therefore, we will focus primarily on *Candida* spp., the most prevalent species and the most common cause of both life-threatening invasive disease and clinically important mucosal diseases, such as vulvovaginal candidiasis, thrush and oesophagitis.

Antifungal drug resistance rates in *Candida* species are dynamic and variable between medical institutions and countries⁷. The highest rates of both azole and echinocandin resistance are observed in *Candida glabrata*

in this Review that tolerance and trailing growth in fluconazole probably reflect the same phenomenon^{19–21}.

Moreover, the ability of *Candida* spp. to form biofilms and the phenomenon known as paradoxical growth also affect fungal interaction with drugs. *Candida* spp. biofilms induce a transient, physiological alteration in drug responses²² (BOX 3); that is, fungal biofilms exhibit reduced antifungal drug susceptibility via mechanisms that are dependent on cells growing within a biofilm, in which cells adhere to a substrate and form a thick mat of cells and secreted extracellular matrix that holds them together and reduces drug efficacy. The


and *Candida tropicalis*³¹ (TABLE 1). The most prevalent mechanism of azole resistance involves increased drug efflux pump activity, primarily due to gain-of-function

Box 2 | Antifungal heteroresistance

Heteroresistant clinical isolates contain a small subpopulation of cells (usually <<1%) that grow at drug concentrations \geq eightfold higher than the majority of the population¹¹. Heteroresistance is detected, and distinguished from tolerance, by population analysis profiling assays (see the figure, part a) that measure the proportion of cells growing at a range of drug concentrations. For *Candida glabrata*, upon a second exposure to drug, heteroresistant subpopulations again produce a subpopulation that grows, despite the presence of the drug; thus, heteroresistance is not equivalent to genetic resistance.

Antifungal heteroresistance was first reported for *Cryptococcus neoformans* and *Cryptococcus gattii*^{97,98} and is an intrinsic property of these species^{98,99}. Extra copies of an individual chromosome are associated with cryptococcal heteroresistant isolates; the degree to which heteroresistance is due to a particular aneuploidy seems to be strain specific¹⁰⁰. In *Cryptococcus*, one molecular mechanism of heteroresistance seems to involve extra copies of the chromosome carrying both *ERG11*, the target of azoles, and *AFR1*, a major efflux pump. However, some *Cryptococcus* heteroresistant isolates do not have obvious aneuploidies¹⁰¹. *C. glabrata* isolates exhibit a range of heteroresistance levels and highly heteroresistant isolates exhibit increased levels of efflux activity⁹⁷; however, the molecular mechanisms that yield heteroresistance in *C. glabrata* and in non-aneuploid *Cryptococcus* isolates are not known.

Very few studies have analysed the role of heteroresistance in in vivo persistence of a fungal pathogen in animal tissues after antifungal treatment. In vivo persistence of *C. glabrata* was compared using strains with low and high heteroresistance that had the same susceptible minimum inhibitory concentration. In a mouse assay that monitored colony-forming units (CFU) in kidneys 7 days after infection and fluconazole treatment⁹⁷ (see the figure, panel b), resistant isolates demonstrated a high fungal burden in the kidney in all mice, consistent with a failure to respond to the drug. Mice infected with the susceptible strain having low heteroresistance levels had a lower proportion of the mice with detectable *C. glabrata* in the kidneys compared with mice that were infected with an isolate that had high heteroresistance levels (numbers of mice with detectable *C. glabrata* are indicated). This result is consistent with the idea that high heteroresistance may underlie in vivo persistence of *C. glabrata* infections.



Box figure part b is adapted from REF.⁹⁷, CC BY 4.0 (<https://creativecommons.org/licenses/by/4.0/>).

mutations in transcription factors that regulate ATP-binding cassette (ABC) transporters (*TAC1* in *C. albicans* and *PDR1* in *C. glabrata*) and major facilitator superfamily pumps (*MRR1* in *C. albicans*)^{32,33}. Of note, many of these transcription factors also regulate other genes that contribute to resistance, virulence or general yeast cell fitness³³. Furthermore, because of the overlapping functions of different efflux pumps, mutations such as loss of function of a single gene encoding an efflux pump or gain of function of less efficient efflux pumps have only modest effects on bona fide resistance, and the most dramatic effects are from overexpression combined with homozygosity (loss of heterozygosity (LOH)) of hyperactive transcription factor alleles^{34,35}.

Alterations in antifungal drug targets, owing to increased target expression or mutations within the target protein sequence, also mediate antifungal drug resistance (TABLE 1). *Erg11*, which is the target of azoles, is a cytochrome P450-dependent lanosterol 14 α -demethylase required for ergosterol biosynthesis. In *C. albicans*, gain-of-function mutations in *UPC2*, which encodes a key transcriptional regulator of ergosterol biosynthetic genes³⁶, lead to increased *ERG11* expression and reduced azole susceptibility. Increased *ERG11* expression is also seen in intrinsically resistant non-*C. albicans* species; however, the underlying mechanism is unknown. Mutations in *ERG11* have also been observed in *Candida* spp., and over 100 different *ERG11* alleles have been described³⁷.

Many *ERG11* mutations seem to interfere with drug binding and to decrease susceptibility in an additive manner³⁸. Finally, in *Candida auris*, *ERG11* polymorphisms as well as an increased number of *ERG11* gene copies are thought to be responsible for its largely intrinsic azole resistance^{35,39–41}. *C. auris* was discovered only a decade ago⁴² and has led to major outbreaks that have shuttered or paralyzed hospital wards. *C. auris* appears to rapidly acquire resistance or tolerance to echinocandins as well polyenes⁴³, leaving few, if any, treatment options. Its ability to survive and adhere to surfaces over long time periods also makes *C. auris*-contaminated areas difficult to decontaminate. How *C. auris* rapidly acquires drug resistance and/or tolerance to the remaining antifungal drug classes is only beginning to be explored.

Copy number variations, including whole-chromosome aneuploidy and shorter-range amplifications, are genome changes that can increase resistance^{33,44–50}. For example, isochromosome (5L), a specific aneuploidy in *C. albicans*, results in the formation of two extra copies of the left arm of chromosome 5 (REF.⁴⁴), and, consequently, extra copies of *TAC1* and *ERG11*, genes that confer resistance to azoles in these strains⁵¹. Similarly, extra copies of the right arm of chromosome 3 may increase drug efflux because *CDR1* and *MRR1*, which encode a major ABC transporter and a transcriptional activator of *MDR1* (the major facilitator superfamily transporter), respectively, are found on this chromosome (*Candida* Genome Database). In agreement with this, increased copies of the right arm of chromosome 3 together with unidentified genes on trisomic chromosome 7 were associated with increased efflux⁵².

Box 3 | Fungal biofilms and paradoxical growth responses to antifungals

Biofilms have increased antifungal resistance

The ability of *Candida* species to form biofilms, where they attach to a surface and produce a community of cells with a range of filamentous morphologies surrounded by an extracellular matrix, is not only relevant for their ability to cause disease but also has an enormous effect on fungal interaction with drugs. As with bacterial biofilms, fungi within biofilms are much less susceptible to antifungal drugs¹⁰². Assays used to characterize the susceptibility of planktonic cells are not applicable to *Candida* biofilms because of their physical properties. Methods available to assay antifungal responses within biofilms were recently reviewed^{14,103}. The most widely used method measures the effect of the drug on biofilm metabolism using dyes, such as resazurin or 2,3-bis(2-methoxy-4-nitro-5-sulphophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide reduction (XTT)¹⁰⁴.

The mechanisms that contribute to the decreased susceptibility of cells in the biofilms to antifungal drugs are distinct from those in planktonic cells. Specifically, unlike planktonic cells, efflux pumps and target gene mutations have only a limited role in *Candida* biofilm resistance to drugs, such as fluconazole. Instead, the extracellular matrix of biofilms directly sequesters drugs, such as fluconazole and amphotericin¹⁰⁵. As a result, the major mechanism leading to the resistance of *Candida* biofilms is a decrease in the exposure of the cells within the biofilm to the drug itself, as evidenced by the finding that mutants that fail to generate biofilm-associated extracellular matrix remain susceptible to fluconazole¹⁰⁵. Therefore, exposure of biofilms to a given concentration of drug results in a much lower intracellular concentration of the drug. Furthermore, the resistant state is phenotypic, rather than genetic, as it relies on cells being in a biofilm and is not seen in the planktonic cells shed by the biofilm. Finally, persister cells have been proposed to explain the reduced susceptibility of *Candida* biofilms to fungicidal drugs, such as echinocandins and amphotericin B; however, there are conflicting reports, such that the existence of persister cells in fungal biofilms, and the question of whether rare survivors are dependent on them being in a biofilm, remains controversial in the literature^{106–108}.

Paradoxical growth

A phenomenon that shares some features of tolerance is paradoxical growth, whereby fungal strains are inhibited by low concentrations of a drug, most typically an echinocandin, yet they are able to grow at much higher drug concentrations. The mechanism or mechanisms of paradoxical growth are not yet well understood. Like tolerance, paradoxical growth involves a substantial proportion of the cell population; and it is unlikely to be owing to alterations in the activity or stability of the drug target, β -glucan synthase^{109–111}. A potential mechanistic link between the paradoxical effect and tolerance is their common dependence on stress pathways regulated by heat shock protein 90 (Hsp90) and calcineurin (reviewed elsewhere¹¹²). *Aspergillus nidulans* cells that exhibit paradoxical growth also appear only after relatively long periods of drug exposure and appear to reverse many of the phenotypes associated with the responses of susceptible cells to echinocandins (for example, internalization of the β -glucan synthases (reviewed elsewhere¹¹³)).

For heterozygous diploids, such as *C. albicans*, LOH is another frequent mechanism of resistance (reviewed elsewhere^{53,54}). For example, in a series of clinical *C. albicans* isolates from the same patient with HIV treated with fluconazole^{55,56}, LOH events that were retained in all subsequent isolates arose concomitant with the acquisition of bona fide resistance. These LOH events included homozygosity of a region of the left arm of chromosome 5 that includes a point mutation in *ERG11* (REF.⁵⁶). Homozygosity of this *ERG11* allele was persistent (retained in the infecting population for more than 8 months⁵⁶), consistent with the notion that mutations in *ERG11* promote pathogen survival under drug selection⁵⁷. Finally, some drugs enhance genome instability and, thus, promote aneuploidy and whole-chromosome LOH^{58,59}. For example, exposure to fluconazole promotes whole-chromosome LOH via unusual mitotic divisions (chromosome duplications and losses)^{59–61}. Furthermore, both LOH and aneuploidy occur at much higher frequency (twofold to

fourfold) than point mutations⁶⁰, and are readily detected following a single passage through the bloodstream or oral cavity of a mouse^{62–64}.

Recent guidelines from the Infectious Disease Society of America recommend that an echinocandin, rather than azoles, be used as initial therapy for most invasive *Candida* spp. infections²³. Echinocandin resistance is almost exclusively due to mutations in *FKS* genes (TABLE 1), which encode the target enzyme of the drug, 1,3- β -glucan synthase⁶⁵. Echinocandin resistance is less prevalent than azole resistance (less than 1% of *C. albicans* infections⁷, but up to 10% of *C. glabrata* infections⁶⁶). Point mutations in one of two specific hotspot regions of *FKS* genes increase the half-maximal inhibition concentration of an echinocandin in vitro by up to three orders of magnitude⁶⁷. Of note, long periods of echinocandin therapy are associated with the emergence of echinocandin-resistant strains⁶⁵. In addition, a substantial number of infections with echinocandin-susceptible *C. glabrata* or *C. albicans* isolates are not readily cleared⁶⁸, and the degree to which echinocandin tolerance may play a role in this remains to be determined.

The emergence of multidrug-resistant *C. glabrata* isolates is increasing at an alarming rate. A hypermutation mechanism was proposed to drive this multidrug-resistant phenotype and was thought to be attributable to variant alleles of *MSH2*, a DNA repair gene; however, more recent work did not find a correlation between *MSH2* mutations and antifungal resistance in vitro or in vivo^{69,70}. Regardless of the mechanism, the emergence of multidrug-resistant *C. glabrata*⁷¹ is a major concern, because it leaves the polyene amphotericin B, which is toxic⁸, as the only treatment option for these infections.

Antifungal drug tolerance**Measuring and characterizing tolerance in fungi.**

Antifungal tolerance is a characteristic of drug-susceptible strains that have the ability to grow slowly at inhibitory drug concentrations; usually, only some of the cells in a given population exhibit this slow growth. Tolerance has been measured and characterized most extensively in *C. albicans* isolates treated with fluconazole, although tolerance is also observed in most *Candida* species for other drugs. The clinical importance of tolerance and/or trailing remains an open question (BOX 4).

Several features distinguish fungal tolerance from fungal resistance: tolerant cell growth is slower and more time dependent than resistant cell growth and is less dependent on the drug concentration⁹. In addition, different clinical isolates exhibit different levels of tolerance, measured as the proportion of growth above the MIC at 48 h in disc diffusion or broth microdilution assays (BOX 1). The degree of tolerance correlates with the size of the subpopulation of cells that grow above the MIC and the rate at which such cells form visible colonies at supra-MIC concentrations⁹. This correlation highlights the idea that tolerance is owing to the slow growth of some cells in the population and raises questions about how such cells differ from those that do not grow (or grow much more slowly).

Box 4 | Clinical relevance of fungal tolerance


The clinical implications of fungal tolerance, also termed trailing growth in the clinical literature, remain to be resolved. The 24-h clinical end point for standardized minimum inhibitory concentration (MIC) assays was established to minimize the detection of trailing growth, based largely on studies that failed to find a positive correlation between trailing and virulence or mortality^{113–115}. For example, *Candida albicans* and *Candida tropicalis* trailing isolates with similar MICs showed no difference in response to fluconazole (FLC) in a mouse model for up to 5 days after infection¹¹⁶, supporting the recommendation of a 24-h MIC end point. One caveat is that the study involved only a single isolate with a high level of trailing growth from each species; a second issue is that longer-term clinical outcomes, such as infection recurrence, were not investigated. This is particularly important as the effect of tolerance on infection persistence may take time to be detected. We posit that the ability of the fungus to continue to divide, even slowly, in the presence of a drug in the host may be an important contributor to recurrent infections as well as to the ability to acquire drug resistance.

A large clinical study analysed 690 *Candida* isolates (eight species, nine antifungals and isolates collected from 29 hospitals)¹¹³, with 83% of the ‘trailing’ isolates having <50% residual growth and not significantly affecting clinical outcomes. However, trailing of >50% was not analysed separately. A more recent study of *C. tropicalis* isolates defined trailing levels as weak, moderate and heavily trailing (<25%, 26–50% and >50% residual growth, respectively); these isolates were tested in *Galleria* larvae and two mouse models¹⁵. In all three models, heavily trailing isolates (which made up ~7% of the isolates) responded poorly to FLC, leading the authors to suggest that they should be regarded as clinically resistant to FLC. They also recommended that caution should be exercised in using FLC to treat patients infected with isolates that have moderate trailing levels¹⁵.

A small-scale retrospective study (19 patients) compared the tolerance levels of *C. albicans* strains isolated from patients treated with FLC whose infections were rapidly cleared by FLC with strains isolated from patients in which candidaemia was persistent because FLC failed to clear the infection¹¹⁷. Initial isolates (prior to antifungal therapy) from the cleared infections consistently had lower levels of tolerance (see the figure), relative to the isolates that caused persistent infections (those that are not cleared by drug treatment). This suggests that tolerance may affect the efficacy of FLC treatment and supports the idea that retrospective, as well as prospective, studies should be conducted to test the relationship between patient outcome and the initial tolerance level of the infecting isolates.

Clearly, it will be important to conduct additional studies that quantify tolerance in large numbers of diverse isolates and their known clinical outcomes. Moving forward, in vivo experiments will also be important. It is crucial to evaluate clinical isolates displaying a wide range of in vitro tolerance phenotypes, particularly if clinical data regarding patient outcome are available. It is well accepted that diverse *C. albicans* isolates exhibit heterogeneity with respect to the expression of virulence traits and determinants of pathogenicity^{118,119}. Although the heterogeneity of clinical responses to treatment is likely to be multifactorial, improved methods to systematically characterize tolerance can address the degree to which tolerance contributes to this heterogeneity.

Blue dots represent isolates that caused non-persistent infections; coloured dots represent isolates that caused persistent infections. ***t test, $P < 0.001$. Box figure is adapted from REF.⁹, CC BY 4.0 (<https://creativecommons.org/licenses/by/4.0/>).



Trailing growth

Generally defined as reduced but persistent visible growth of *Candida* spp. at fluconazole concentrations above the minimum inhibitory concentration (MIC). Trailing has also been described as an increase in the MIC during growth beyond 24 h (the standard end point for MIC measurements for *Candida* spp.) and can be measured as the residual yeast growth at fluconazole concentrations above the MIC. Trailing was quantified in a recent study as the percentage of residual yeast growth at fluconazole concentrations above the MIC in each well and mean trailing as the geometric mean of trailing observed in all of the wells above the MIC.

The degree of tolerance varies across different isolates, presumably owing to the intrinsic allele diversity of each isolate. Phenotypic differences between clinical isolates involve many thousands to tens of thousands of single-nucleotide polymorphisms and are also evident with phenotypes such as biofilm formation and its dependence upon specific transcription factors⁷². In this sense, the differences in tolerance levels measured as the fraction of growth or SMG (BOX 1) between isolates have a genetic component. By contrast, for a single isolate, the phenotypic heterogeneity that drives some cells to grow slowly, and others to arrest growth, must be owing to physiological or metabolic shifts that differ between isogenic cells in the population.

Mechanisms of antifungal tolerance. Although the mechanisms by which clinical responses to treatment vary are likely to be multifactorial, the ability to quantitatively characterize tolerance will permit the examination of these mechanisms. In addition to heterogeneity between isolates, there is heterogeneity within a population, in that different colonies of the same sample behave differently when exposed to fluconazole. Upon exposure to fluconazole, all cells undergo one to three rounds of division before growth arrest^{9,59}; tolerant cells in the

population resume growth several hours later, whereas non-tolerant cells arrest for considerably longer and only resume division in the absence of the drug. Furthermore, colonies from higher-tolerance isolates appear faster than those from low-tolerance isolates (FIG. 1c). Thus, tolerance is likely to be owing to physiological responses that emerge heterogeneously among the cell population, where the proportion of cells exhibiting such responses is a function of the genetic potential of the specific isolate. Point mutations that affect this genetic potential remain to be identified, partly because it is difficult to screen for recessive mutations in this heterozygous diploid organism and because unrelated clinical isolates can diverge at tens of thousands of loci. Newly available haploid isolates of *C. albicans*⁷³ have the potential to facilitate screens for recessive point mutations and insertion mutants^{74,75}. For example, this approach identified sphingolipid biosynthesis as an important mechanism by which cells survive azole-induced ergosterol depletion⁷³.

Aneuploidy and loss of heterozygosity are rapidly acquired genome changes that can result in increased tolerance and are likely to affect one or several genes that alter the tolerance level. Importantly, exposure to azoles promotes mitotic defects that yield tetraploid and aneuploid cells⁵⁹. Aneuploidy can alter fluconazole

Paradoxical growth

Also referred to as the Eagle effect. The ability of a fungal isolate to reconstitute growth in the presence of high drug concentrations, but being fully susceptible at lower concentrations. Paradoxical growth appears with a delay of one to several days, but resembles growth in the absence of the drug. Paradoxical growth has been reported primarily for echinocandins.

Adjuvants

A drug that potentiates the effect of an anti-infective, but is not an anti-infective on its own.

tolerance in *C. albicans*^{39,52}. For example, segmental trisomy of chromosome 3 conferred an increased fitness in the presence of fluconazole that was attributable, at least partially, to extra copies of *NPR2*, which encodes a urea transporter⁵². This is tolerance, rather than resistance, because the MIC remained susceptible and the increased growth was detected after incubation for more than the 24 h in standard MIC assays. Notably, a single aneuploid chromosome can confer more than one unrelated phenotype. Trisomy of chromosome 2 promotes the growth of *C. albicans* cells in the presence of the antifungal drug caspofungin⁴⁸ without altering the MIC. Interestingly, trisomy of chromosome 2 also promotes cell survival in the presence of hydroxyurea, a cancer chemotherapy drug. The response to hydroxyurea was shown to be dependent on two of the 1,087 different genes located on chromosome 2, *RNR1* and *RNR21*; the genes responsible for survival in the presence of

caspofungin are distinct from these *RNR* genes and have not yet been identified⁴⁸. This further suggests that exposure to hydroxyurea, by selecting for chromosome 2 trisomy, has the potential to increase the subsequent survival of *C. albicans* cells exposed to caspofungin.

Adjuvant drugs and mutations that affect several stress-responsive pathways often reduce tolerance⁹ (BOX 5), and adjuvants reduce tolerance to similar baseline levels irrespective of the tolerance level of the isolate⁹. This implies that tolerance depends on a shared set of critical pathways across diverse isolates. It also suggests that drugs that interfere with tolerance may be useful in combination therapies that extend the useful lifespan of currently available antifungal drugs (BOX 5).

In addition to genetic determinants of the tolerance level, growth conditions influence the degree of tolerance exhibited by a strain. For example, conditions that increase cell wall chitin promote cell survival in



Box 5 | Synergistic drug combinations in vitro and in vivo

Synergistic combinations of fluconazole (FLC) and an adjuvant drug are active, and often cidal, against *Candida albicans* in vitro. A series of adjuvant drugs, reported to affect resistance and/or tolerance, were compared across a set of *C. albicans* strains. Most adjuvants, when added to the entire Petri plate, dramatically reduced the fraction of growth (FoG) measured as growth within the zone of inhibition surrounding a disc containing FLC (see the figure, part a). This included inhibitors of heat shock protein 90 (Hsp90) (geldanamycin and radicicol), calcineurin (cyclosporin A and FK506), target of rapamycin (TOR) (rapamycin), the unfolded protein response (tunicamycin) and sphingolipid biosynthesis (aureobasidin A), as well as antibacterials^{120,121}, anti-arrhythmic agents (amiodarone)¹²², immunosuppressive agents (FK506)¹²³, antidepressants (fluoxetine)¹²⁴, antipsychotics (fluphenazine (FNZ)) and non-steroidal anti-inflammatory agents (ibuprofen)¹²⁵. The minimum inhibitory concentration (radius of zone of inhibition) is largely unaffected by these adjuvants, supporting the idea that the adjuvants mainly inhibit tolerance rather than resistance. Within the zone of inhibition, cells are not viable^{9,21,126}, which indicates that the adjuvants in combination with FLC are fungicidal.


Drug combinations that reduce FLC tolerance have been examined in several animal studies and in one small-scale retrospective analysis of patient outcomes. A study tested the combination of FLC and the immunosuppressant cyclosporine, which is fungicidal and affects tolerance but not resistance²¹, in a rat endocarditis model. The cyclosporine–FLC combination was more effective in clearing the infection²¹. Although the authors only tested a single laboratory *C. albicans* isolate, and the concentrations of cyclosporine used in the study were above the corresponding therapeutic dose in humans, this early study suggested that adjuvant drugs that eliminate tolerance may provide a strategy for extending the useful lifespan of FLC (reviewed in REF.⁸⁷). Similarly, although FNZ alone had no effect on survival, the psychotherapeutic agent FNZ combined with FLC prolonged the survival of *Galleria* larvae infected with highly tolerant *C. albicans* isolates (high FoG), but not those infected with low-tolerance isolates (low FoG) (see the figure, part b).

PBS, phosphate-buffered saline. Box figure parts a and b adapted from REF.⁹, CC BY 4.0 (<https://creativecommons.org/licenses/by/4.0/>).


a Effect of adjuvant drugs in combination with FLC



Susceptible laboratory strain derivative with low FoG level



Susceptible laboratory strain derivative with high FoG level



the presence of echinocandin^{76,77}, whereas calcineurin inhibitors reduce echinocandin tolerance (measured using MIC assays analysed after 72 h)^{68,78}. Similarly, the pH, temperature and nutrient availability affect the level of fluconazole tolerance⁹. Thus, tolerance has a genetic component that varies between isolates and a non-genetic component that is influenced by growth conditions and cell physiology.

Two general concepts underlying the mechanisms of fluconazole tolerance need molecular explanations: the inter-isolate heterogeneity of tolerance levels; and the cell-to-cell variation within a given isolate. The inter-isolate heterogeneity is likely due to genetic differences that contribute to several other clinically relevant phenotypes, including biofilm formation, filamentous growth responses and sensitivity to temperature^{53,61,79,80}. Cell-to-cell phenotypic heterogeneity occurs at a frequency that is far too high (10–90% of cells) to be due to the genetic acquisition of mutations, implying that it is due to non-genetic differences between the cells.

Earlier studies identified stress response pathways important for drug responses that are most likely affecting tolerance, although at the time little distinction was made between tolerance and resistance (reviewed elsewhere⁸¹). Inhibitors of heat shock protein 90 (Hsp90)⁸², calcineurin^{21,26,27}, target of rapamycin (TOR)⁸³ and mutants that affect Rim101 (REF.⁸⁴), a transcription factor involved in the pH response pathway, effectively eliminate tolerance and greatly increase the fungicidal activity of fluconazole across a diverse set of isolates with different tolerance levels (FIG. 1e; BOX 5). This implies that tolerance in all strains is dependent on all of these major hubs of cell homeostasis, irrespective of either the subpopulation size or its ability to grow in the presence of the drug. Consistent with this, either pharmacological or genetic disruption of Hsp90, calcineurin, TOR, lysine deacetylases or Rim101 function enhance the effect of fluconazole (reviewed elsewhere⁸⁵). Most, or all, of these fluconazole-associated stress response pathways seem to affect tolerance, because inhibiting these pathways does not affect MIC levels (BOX 5). Importantly, many of these same core stress response pathways in *C. albicans* (Hsp90, Ca²⁺-calmodulin calcineurin, lysine deacetylases, protein kinase C and HOG (high-osmolarity glycerol responses) pathways) also affect echinocandin responses^{68,86,87}. Specifically, studies of these pathways using either inhibitors or mutant strains showed that they reduce fungal growth in combination with caspofungin or anidulafungin. Indeed, the involvement of lysine deacetylases and calcineurin implies a connection between tolerance and the metabolic anti-stress machinery (for example, REF.⁸⁸). Thus, variations in the function of the critical pathways listed above are candidate drivers of differences in tolerance levels between isolates. However, the complex constellation of genes responsible for differences in tolerance levels between isolates and their progeny remains to be explored.

The large number of central cellular pathways that affect tolerance also implies that many types of mutations could lead to changes in tolerance. We posit that inter-isolate heterogeneity in tolerance is a composite

phenotype that emerges from variations at multiple loci; that is, different stress response pathways probably contribute to tolerance to a different degree in different isolates. Accordingly, a current challenge is to systematically study the effects of natural variation in the genes that affect tolerance. Several approaches are likely to be informative: using near-isogenic strains that differ in tolerance levels; engineering candidate mutations in different isolates; and performing unbiased screens for mutants that increase or decrease tolerance without affecting resistance.

Mutations in some pathways seem to affect resistance as well as tolerance. For example, mutations in *TAC1*, which encodes a positive transcriptional regulator of efflux pump genes, increases efflux activity⁵⁰. In addition to affecting resistance, drug uptake and efflux appear to contribute, at least partially, to tolerance⁹, based on studies with fluorescent azole probes and strains with similar MIC levels but different tolerance levels (measured as the fraction of growth and SMG, see BOX 1)^{89,90}. Transcription factors can regulate multiple targets, and therefore the downstream effects of mutations in those transcription factors on resistance and tolerance could be independent of one another. Alternatively, the stress pathways important for tolerance may indirectly modify efflux activity, thereby enabling cells to grow slowly in the presence of the drug. Thus, although resistance and tolerance are different (as described above), they may share the same processes (albeit to different degrees) to promote growth in the presence of antifungal drugs.

For example, isolates that are more tolerant have lower average intracellular drug concentrations than less tolerant isolates⁹ (FIG. 1d). Furthermore, intracellular drug concentrations vary among cells within a given isolate, with the more tolerant isolates (those that grow slowly) having a larger population of cells with moderate amounts of drug per cell. By contrast, an isolate that is resistant because of increased efflux has a proportion of cells with very low levels of intracellular drug (10× less than those with moderate drug levels compared with tolerant isolates)⁹ (FIG. 1d). This suggests a mechanistic distinction between resistance and tolerance. In resistant isolates, mutations (for example, gain-of-function alleles in drug efflux pumps or their positive regulators) affecting efflux would enable most (or all) cells to reduce the intracellular drug concentration to very low levels. In tolerant isolates, physiological differences (for example, normal distribution in the amount of efflux gene expression) would enable some cells to reduce intracellular drug concentrations modestly relative to others, thereby facilitating slow growth in those cells with higher efflux gene expression. This idea is consistent with the results thus far⁹; more isolates with characterized mechanisms of resistance or tolerance will need to be tested to determine whether it is generalizable.

Moreover, the molecular processes that contribute to the cell-to-cell phenotypic heterogeneity within an isogenic population are beginning to be elucidated. We do not yet know the degree to which a given daughter cell in a population inherits the phenotypic characteristics of its mother: for example, whether tolerant mother cells are more likely to have tolerant daughter cells, or

Fungicidal activity
Drugs with fungicidal activity reduce a population of cells by >99.9% or 3 log₁₀ units at a concentration equal to or greater than the minimum inhibitory concentration.

whether the degree of drug response is distributed randomly among the progeny. The phenotypic differences between cells can be the consequence of cell-to-cell differences in the gene expression state (for example, via chromatin modification and/or copy number variation), the metabolic state (for example, metabolite exchange interactions between cells that specialize metabolically and, as a consequence, diverge phenotypically (reviewed elsewhere⁹¹)) and/or the biophysical state (via the formation of macromolecular condensates, such as stress granules, prions and prion-like aggregates and/or phase transitions (reviewed elsewhere⁹²)). These different states are not mutually exclusive, and they may require a similar set of pathways that affect azole tolerance (for example, Hsp90 and TOR)⁹³. Once the state or states that affect tolerance are better understood, it will be possible to address critical mechanistic questions, such as how the state of tolerant versus non-tolerant individual cells is maintained in a given cell and its progeny during growth in the presence of drug, and why that state is not present in other cells in the population.

Organelles, such as the vacuole, make important contributions to tolerance and/or trailing growth. In *Saccharomyces cerevisiae*, several genes involved in retrograde trafficking modulate tolerance and/or trailing growth, including *VPS21* (REFS^{28,52}), *VPS15* and *VPS51* (REF⁹⁴); Rim101 may influence tolerance via its ability to regulate the transcription of key components of the vacuolar trafficking pathway⁹⁵. Thus, tolerance seems to depend on intracellular processes that facilitate adaptation in response to drug stresses. Clearly, as the molecular and cellular mechanisms of tolerance, as well as the clinical implications of tolerance, become clearer, it may be possible to design therapeutic strategies that inhibit tolerance and provide new avenues to treat fungal infections.

Role of tolerance in the acquisition of resistance. Tolerance has been proposed to increase the frequency of antifungal resistance⁸². In part, this argument is based on the observation that inhibition of Hsp90 in the presence of fluconazole not only eliminates tolerance⁹ but also renders fluconazole fungicidal⁸⁷. Thus, no colonies grow when fluconazole and an Hsp90 inhibitor are combined, because dead cells cannot evolve. Nonetheless, because a highly tolerant strain will divide more frequently in the

presence of fluconazole than a strain with low tolerance levels, it will also have a higher population size and a higher likelihood of acquiring new mutations. In addition, drug pressure will lead to the positive selection of mutants that exhibit improved fitness. It will be important to determine the degree to which the population size, mutation rate and selection pressure contribute to antifungal responses in tolerant cells and to the rate of the emergence of resistance.

Summary and future directions

In this Review, we distinguish between antifungal resistance and tolerance, clarifying terms that have been used interchangeably in the literature, to describe growth in the presence of an inhibitory drug. Resistance is owed to genetic changes that directly affect the drug target and/or intracellular drug concentrations and cause a heritable effect on the entire population of cells in a given isolate. By contrast, tolerance is a feature of susceptible (non-resistant) isolates that relies upon several central stress response pathways; it is a consequence of phenotypic heterogeneity, in which some cells in the population grow, albeit slowly, in the drug. Differences in tolerance levels between isolates is assumed to have a genetic basis and to affect the proportion of cells able to grow in the drug. The mechanisms that drive cell-to-cell differences in drug responses within a single isolate remain to be determined, but, at least for azoles, they seem to be connected to differences in intracellular drug concentration between different cells.

Combination therapies with adjuvant drugs that interfere with the compensatory stress responses required for tolerance have the potential to increase the lethality of an inhibitory antifungal drug. However, the ability of many molecules to achieve exactly these purposes in vitro is only a first step; very few adjuvants have progressed to efficacy studies in animal models of infection. Furthermore, to date, most studies have not considered the role of tolerance in the efficacy of the drug combinations. Nonetheless, systematic and large-scale screens for molecules that affect tolerance provide a promising approach to overcoming antifungal drug resistance and improving the care of patients with fungal infections (see Supplementary information).

Published online: 11 February 2020

1. Arendrup, M. C. & Patterson, T. F. Multidrug-resistant *Candida*: epidemiology, molecular mechanisms, and treatment. *J. Infect. Dis.* **216**, S445–S451 (2017).
2. Perlín, D. S., Rautema-Richardson, R. & Alastruay-Izquierdo, A. The global problem of antifungal resistance: prevalence, mechanisms, and management. *Lancet Infect. Dis.* **17**, e383–e392 (2017).
3. Alangaden, G. J. Nosocomial fungal infections: epidemiology, infection control, and prevention. *Infect. Dis. Clin. North Am.* **25**, 201–225 (2011).
4. Andes, D. R. et al. The epidemiology and outcomes of invasive *Candida* infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). *Transpl. Infect. Dis.* **18**, 921–931 (2016).
5. Krysan, D. J. The unmet clinical need of novel antifungal drugs. *Virulence* **8**, 135–137 (2017).
6. Bassetti, M., Carnelutti, A., Castaldo, N. & Peghin, M. Important new therapies for methicillin-resistant *Staphylococcus aureus*. *Expert Opin. Pharmacother.* **20**, 2317–2334 (2019).
7. Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M. & Jones, R. N. Twenty years of the SENTRY antifungal surveillance program: results for *Candida* species from 1997–2016. *Open Forum Infect. Dis.* **6**, S79–S94 (2019).
8. Lepak, A. J. & Andes, D. R. Antifungal pharmacokinetics and pharmacodynamics. *Cold Spring Harb. Perspect. Med.* **5**, a019653 (2014).
9. Rosenberg, A. et al. Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia. *Nat. Commun.* **9**, 2470 (2018).
10. This article provides a quantitative characterization of fluconazole tolerance in *C. albicans*, distinguishing it from resistance and highlighting its phenotypic heterogeneity and association with subpopulation growth, and sensitivity to adjuvant drugs.
11. Balaban, N. Q. et al. Definitions and guidelines for research on antibiotic persistence. *Nat. Rev. Microbiol.* **14**, 320–330 (2016).
12. Brauner, A., Shores, N., Fridman, O. & Balaban, N. Q. An experimental framework for quantifying bacterial tolerance. *Biophys. J.* **112**, 2664–2671 (2017).
13. Levin-Reisman, I., Fridman, O. & Balaban, N. Q. ScanLag: high-throughput quantification of colony growth and lag time. *J. Vis. Exp.* <https://doi.org/10.3791/51456> (2014).
14. Wuyts, J., Van Dijck, P. & Holtappels, M. Fungal persister cells: the basis for recalcitrant infections? *PLoS Pathog.* **14**, e1007301 (2018).
15. Astvad, K. M. T., Sanglard, D., Delarue, E., Hare, R. K. & Arendrup, M. C. Implications of the EUCAST trailing phenomenon in *Candida tropicalis* for the in vivo susceptibility in invertebrate and murine models. *Antimicrob. Agents Chemother.* **62**, e01624–18 (2018).

16. Marcos-Zambrano, L. J., Escribano, P., Sanchez-Carrillo, C., Bouza, E. & Guinea, J. Scope and frequency of fluconazole trailing assessed using EUCAST in invasive *Candida* spp. isolates. *Med. Mycol.* **54**, 733–739 (2016).
17. Coenye, T., De Vos, M., Vandenbosch, D. & Nelis, H. Factors influencing the trailing endpoint observed in *Candida albicans* susceptibility testing using the CLSI procedure. *Clin. Microbiol. Infect.* **14**, 495–497 (2008).
18. Agrawal, D., Patterson, T. F., Rinaldi, M. G. & Revankar, S. G. Trailing end-point phenotype of *Candida* spp. in antifungal susceptibility testing to fluconazole is eliminated by altering incubation temperature. *J. Med. Microbiol.* **56**, 1003–1004 (2007).
19. Marr, K. A., Rustad, T. R., Rex, J. H. & White, T. C. The trailing end point phenotype in antifungal susceptibility testing is pH dependent. *Antimicrob. Agents Chemother.* **43**, 1383–1386 (1999).
20. Delarue, E. & Sanglard, D. Defining the frontiers between antifungal resistance, tolerance and the concept of persistence. *Drug Resist. Updat.* **23**, 12–19 (2015).
21. Marchetti, O., Moreillon, P., Glauser, M. P., Bille, J. & Sanglard, D. Potent synergism of the combination of fluconazole and cyclosporine in *Candida albicans*. *Antimicrob. Agents Chemother.* **44**, 2373–2381 (2000).
22. Taff, H. T., Mitchell, K. F., Edward, J. A. & Andes, D. R. Mechanisms of *Candida* biofilm drug resistance. *Future Microbiol.* **8**, 1325–1337 (2013).
23. Pappas, P. G. et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. *Clin. Infect. Dis.* **62**, 409–417 (2016).
24. Meletiadis, J., Curfs-Breuker, I., Meis, J. F. & Mouton, J. W. In vitro antifungal susceptibility testing of *Candida* isolates with the EUCAST methodology, a new method for ECOFF determination. *Antimicrob. Agents Chemother.* **61**, e02372–16 (2017).
25. Lockhart, S. R., Ghannoum, M. A. & Alexander, B. D. Establishment and use of epidemiological cutoff values for molds and yeasts by use of the Clinical and Laboratory Standards Institute M57 standard. *J. Clin. Microbiol.* **55**, 1262–1268 (2017).
- This review provides an important and accessible over-review of the concept of epidemiological cut-off values as well as the methodology that underlies their establishment.**
26. Onyewu, C., Wormley, F. L. Jr., Perfect, J. R. & Heitman, J. The calcineurin target, Crz1, functions in azole tolerance but is not required for virulence of *Candida albicans*. *Infect. Immun.* **72**, 7330–7333 (2004).
27. Sanglard, D., Ischer, F., Marchetti, O., Entenza, J. & Bille, J. Calcineurin A of *Candida albicans*: involvement in antifungal tolerance, cell morphogenesis and virulence. *Mol. Microbiol.* **48**, 959–976 (2003).
28. Luna-Tapia, A., Tournu, H., Peters, T. L. & Palmer, G. E. Endosomal trafficking defects can induce calcium-dependent azole tolerance in *Candida albicans*. *Antimicrob. Agents Chemother.* **60**, 7170–7177 (2016).
29. Luna-Tapia, A., Butts, A. & Palmer, G. E. Loss of C-5 sterol desaturase activity in *Candida albicans*: azole resistance or merely trailing growth? *Antimicrob. Agents Chemother.* **63**, e00129–11 (2019).
30. van der Linden, J. W. et al. Aspergillus due to voriconazole highly resistant *Aspergillus fumigatus* and recovery of genetically related resistant isolates from domiciles. *Clin. Infect. Dis.* **57**, 513–520 (2013).
31. McCarty, T. P. & Pappas, P. G. Invasive candidiasis. *Infect. Dis. Clin. North Am.* **30**, 103–124 (2016).
32. Prasad, R., Rawal, M. K. & Shah, A. H. *Candida* efflux ATPases and antiporters in clinical drug resistance. *Adv. Exp. Med. Biol.* **892**, 351–376 (2016).
33. Sasse, C. et al. The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in *Candida albicans*. *Mol. Microbiol.* **86**, 539–556 (2012).
- This article shows that when a strain accumulates multiple resistance mutations that affect different transcription factors, the effects are independent and additive. In addition, these effects, generated by engineered deletion mutations, are associated with reduced fitness in the absence of drug stress. As many resistant isolates do not have obvious fitness defects, it is assumed that they must have acquired compensatory mechanisms in addition to the characterized mechanisms of drug resistance.**
34. Holmes, A. R. et al. Heterozygosity and functional allelic variation in the *Candida albicans* efflux pump genes *CDR1* and *CDR2*. *Mol. Microbiol.* **62**, 170–186 (2006).
35. Munoz, J. F. et al. Genomic insights into multidrug-resistance, mating and virulence in *Candida auris* and related emerging species. *Nat. Commun.* **9**, 5346 (2018).
36. Flowers, S. A. et al. Gain-of-function mutations in *UPC2* are a frequent cause of *ERG11* upregulation in azole-resistant clinical isolates of *Candida albicans*. *Eukaryot. Cell* **11**, 1289–1299 (2012).
- This study establishes that gain-of-function mutations in *UPC2*, the key regulator of ergosterol biosynthesis gene expression, are a source of clinically important fluconazole resistance. Previously, only transcriptional regulators of efflux pump expression were known to do so.**
37. Xiang, M. J. et al. *ERG11* mutations associated with azole resistance in clinical isolates of *Candida albicans*. *FEMS Yeast Res.* **13**, 386–393 (2013).
38. Flowers, S. A., Colon, B., Whaley, S. G., Schuler, M. A. & Rogers, P. D. Contribution of clinically derived mutations in *ERG11* to azole resistance in *Candida albicans*. *Antimicrob. Agents Chemother.* **59**, 450–460 (2015).
39. Healey, K. R. et al. Limited *ERG11* mutations identified in isolates of *Candida auris* directly contribute to reduced azole susceptibility. *Antimicrob. Agents Chemother.* **62**, e01427–18 (2018).
40. Chowdhary, A. et al. A multicentre study of antifungal susceptibility patterns among 350 *Candida auris* isolates (2009–17) in India: role of the *ERG11* and *FKS1* genes in azole and echinocandin resistance. *J. Antimicrob. Chemother.* **73**, 891–899 (2018).
41. Lockhart, S. R. et al. Simultaneous emergence of multidrug-resistant *Candida auris* on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. *Clin. Infect. Dis.* **64**, 134–140 (2017).
42. Satoh, K. et al. *Candida auris* sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. *Microbiol. Immunol.* **53**, 41–44 (2009).
43. Kordalewska, M. et al. Understanding echinocandin resistance in the emerging pathogen *Candida auris*. *Antimicrob. Agents Chemother.* **62**, e00238–18 (2018).
44. Selmecki, A., Forche, A. & Berman, J. Aneuploidy and isochromosome formation in drug-resistant *Candida albicans*. *Science* **313**, 367–370 (2006).
45. Anderson, M. Z., Saha, A., Haseeb, A. & Bennett, R. J. A chromosome 4 trisomy contributes to increased fluconazole resistance in a clinical isolate of *Candida albicans*. *Microbiology* **163**, 856–865 (2017).
46. Yang, F. et al. Tolerance to caspofungin in *Candida albicans* is associated with at least three distinctive mechanisms that govern expression of FKS genes and cell wall remodeling. *Antimicrob. Agents Chemother.* **61**, e00071–17 (2017).
47. Yang, F., Kravets, A., Bethlendi, G., Welle, S. & Rustchenko, E. Chromosome 5 monosomy of *Candida albicans* controls susceptibility to various toxic agents, including major antifungals. *Antimicrob. Agents Chemother.* **57**, 5026–5036 (2013).
48. Yang, F. et al. Aneuploidy enables cross-adaptation to unrelated drugs. *Mol. Biol. Evol.* **36**, 1768–1782 (2019).
49. Todd, R. T., Wikoff, T. D., Forche, A. & Selmecki, A. Genome plasticity in *Candida albicans* is driven by long repeat sequences. *eLife* **8**, e45954 (2019).
50. Coste, A. et al. A mutation in *Tac1p*, a transcription factor regulating *CDR1* and *CDR2*, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in *Candida albicans*. *Genetics* **172**, 2139–2156 (2006).
51. Selmecki, A. M., Dulmage, K., Cowen, L. E., Anderson, J. B. & Berman, J. Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. *PLoS Genet.* **5**, e1000705 (2009).
52. Mount, H. O. et al. Global analysis of genetic circuitry and adaptive mechanisms enabling resistance to the azole antifungal drugs. *PLoS Genet.* **14**, e1007319 (2018).
- This article screens a library of *C. albicans* deletion strains and identifies two genes that affect azole responses, have roles in stress response pathways and functions that are suppressed by the acquisition of aneuploid chromosomes. Whether the mutations are affecting resistance or tolerance is not clear, but activities of the identified genes (vacuolar retrograde trafficking and a cell wall and polarity GTPase activating protein) suggest that the mechanism is involved in processes that affect tolerance rather than in directly affecting resistance.**
53. Todd, R. T., Forche, A. & Selmecki, A. Ploidy variation in fungi: polyploidy, aneuploidy, and genome evolution. *Microbiol. Spectr.* **5**, <https://doi.org/10.1128/microbiolspec.FUNK-0051-2016> (2017).
54. Bennett, R. J., Forche, A. & Berman, J. Rapid mechanisms for generating genome diversity: whole ploidy shifts, aneuploidy, and loss of heterozygosity. *Cold Spring Harb. Perspect. Med.* **4**, a019604 (2014).
55. Ford, C. B. et al. The evolution of drug resistance in clinical isolates of *Candida albicans*. *eLife* **4**, e00662 (2015).
56. White, T. C. Increased mRNA levels of *ERG16*, *CDR*, and *MDR1* correlate with increases in azole resistance in *Candida albicans* isolates from a patient infected with human immunodeficiency virus. *Antimicrob. Agents Chemother.* **41**, 1482–1487 (1997).
- This article presents the first detailed study of the molecular mechanisms underlying the development of fluconazole resistance over time in patients. It is a landmark study because of its patient-based approach and because it yielded strains that are still under study today.**
57. Cowen, L. E. et al. Population genomics of drug resistance in *Candida albicans*. *Proc. Natl. Acad. Sci. USA* **99**, 9284–9289 (2002).
58. Forche, A. et al. The parasexual cycle in *Candida albicans* provides an alternative pathway to meiosis for the formation of recombinant strains. *PLoS Biol.* **6**, e110 (2008).
59. Harrison, B. D. et al. A tetraploid intermediate precedes aneuploid formation in yeasts exposed to fluconazole. *PLoS Biol.* **12**, e1001815 (2014).
60. Forche, A. et al. Stress alters rates and types of loss of heterozygosity in *Candida albicans*. *mBio* **2**, e00129–11 (2011).
61. Ene, I. V. et al. Global analysis of mutations driving microevolution of a heterozygous diploid fungal pathogen. *Proc. Natl. Acad. Sci. USA* **115**, E8688–E8697 (2018).
62. Forche, A. et al. Rapid phenotypic and genotypic diversification after exposure to the oral host niche in *Candida albicans*. *Genetics* **209**, 725–741 (2018).
63. Forche, A., May, G. & Magee, P. T. Demonstration of loss of heterozygosity by single-nucleotide polymorphism microarray analysis and alterations in strain morphology in *Candida albicans* strains during infection. *Eukaryot. Cell* **4**, 156–165 (2005).
64. Forche, A., Magee, P. T., Selmecki, A., Berman, J. & May, G. Evolution in *Candida albicans* populations during a single passage through a mouse host. *Genetics* **182**, 799–811 (2009).
65. Perlín, D. S. Echinocandin resistance in *Candida*. *Clin. Infect. Dis.* **61**, S612–S617 (2015).
66. Farmakiotis, D., Tarrand, J. J. & Kontoyiannis, D. P. Drug-resistant *Candida glabrata* infection in cancer patients. *Emerg. Infect. Dis.* **20**, 1835–1840 (2014).
67. Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D. & Perlín, D. S. Effect of *Candida glabrata* FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3- β -D-glucan synthase: implication for the existing susceptibility breakpoint. *Antimicrob. Agents Chemother.* **53**, 3690–3699 (2009).
68. Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D. & Perlín, D. S. Mechanisms of antifungal drug resistance. *CSH Perspect. Med.* **5**, a019752 (2015).
69. Boddallo-Cardona, M. A. et al. MSH2 gene point mutations are not antifungal resistance markers in *Candida glabrata*. *Antimicrob. Agents Chemother.* **63**, e01876–18 (2019).
70. Singh, A. et al. Absence of azole or echinocandin resistance in *Candida glabrata* isolates in India despite background prevalence of strains with defects in the DNA mismatch repair pathway. *Antimicrob. Agents Chemother.* **62**, e00195–18 (2018).
71. Shor, E., Schuyler, J. & Perlín, D. S. A novel, drug resistance-independent, fluorescence-based approach to measure mutation rates in microbial pathogens. *mBio* **10**, e00120–19 (2019).
72. Ropars, J. et al. Gene flow contributes to diversification of the major fungal pathogen *Candida albicans*. *Nat. Commun.* **9**, 2253 (2018).
73. Hickman, M. A. et al. The ‘obligate diploid’ *Candida albicans* forms mating-competent haploids. *Nature* **494**, 55–59 (2013).
74. Gao, J. et al. *Candida albicans* gains azole resistance by altering sphingolipid composition. *Nat. Commun.* **9**, 4495 (2018).
- This study uses a haploid *C. albicans* isolate and a transposon mutagenesis system to identify mutants that are able to improve growth in very high fluconazole levels. However, the degree to which the mutants are resistant versus tolerant is not addressed, as drug responses did not include MIC assays. The study provides convincing data showing**

- that alterations in the sphingolipid composition of membranes is associated with the ability to grow and divide in the presence of fluconazole.
75. Segal, E. S. et al. Gene essentiality analyzed by in vivo transposon mutagenesis and machine learning in a stable haploid isolate of *Candida albicans*. *mBio* **9**, e02048–18 (2018).
 76. Walker, L. A., Gow, N. A. & Munro, C. A. Elevated chitin content reduces the susceptibility of *Candida* species to caspofungin. *Antimicrob. Agents Chemother.* **57**, 146–154 (2013).
This study finds that the ability of *Candida* species to grow in the presence of sub-MIC levels of caspofungin is associated with increased chitin levels in the cell wall. Pretreatment of cells with CaCl₂ and calcofluor white induces a similar increase in chitin and ability to grow in sub-MIC caspofungin levels. Whether this effect is an alteration in tolerance or resistance levels remains to be determined; higher cell wall chitin levels are induced by reagents, such as CaCl₂ and calcofluor white, and the effect is transient and physiological, thus sharing some features of tolerance.
 77. Lee, K. K. et al. Elevated cell wall chitin in *Candida albicans* confers echinocandin resistance in vivo. *Antimicrob. Agents Chemother.* **56**, 208–217 (2012).
 78. Singh-Babak, S. D. et al. Global analysis of the evolution and mechanism of echinocandin resistance in *Candida glabrata*. *PLoS Pathog.* **8**, e1002718 (2012).
 79. Selmecki, A., Forche, A. & Berman, J. Genomic plasticity of the human fungal pathogen *Candida albicans*. *Eukaryot. Cell* **9**, 991–1008 (2010).
 80. Sitterle, E. et al. Within-host genomic diversity of *Candida albicans* in healthy carriers. *Sci. Rep.* **9**, 2563 (2019).
 81. Cowen, L. E. Hsp90 orchestrates stress response signaling governing fungal drug resistance. *PLoS Pathog.* **5**, e1000471 (2009).
 82. Cowen, L. E. & Lindquist, S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. *Science* **309**, 2185–2189 (2005).
 83. Khandelwal, N. K. et al. Azole resistance in a *Candida albicans* mutant lacking the ABC transporter CDR6/ROA1 depends on TOR signaling. *J. Biol. Chem.* **293**, 412–432 (2018).
 84. Garnaud, C. et al. The Rim pathway mediates antifungal tolerance in *Candida albicans* through newly identified Rim101 transcriptional targets, including Hsp90 and Ipt1. *Antimicrob. Agents Chemother.* **62**, e01785-17 (2018).
 85. Robbins, N., Caplan, T. & Cowen, L. E. Molecular evolution of antifungal drug resistance. *Annu. Rev. Microbiol.* **71**, 753–775 (2017).
 86. Shapiro, R. S., Zaas, A. K., Betancourt-Quiroz, M., Perfect, J. R. & Cowen, L. E. The Hsp90 co-chaperone Sgt1 governs *Candida albicans* morphogenesis and drug resistance. *PLoS One* **7**, e44734 (2012).
 87. Cowen, L. E. et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. *Proc. Natl Acad. Sci. USA* **106**, 2818–2823 (2009).
 88. Olin-Sandoval, V. et al. Lysine harvesting is an antioxidant strategy and triggers underground polyamine metabolism. *Nature* **572**, 249–253 (2019).
 89. Benhamou, R. I. et al. Real-time imaging of the azole class of antifungal drugs in live *Candida* cells. *ACS Chem. Biol.* **12**, 1769–1777 (2017).
 90. Benhamou, R. I., Bibi, M., Berman, J. & Fridman, M. Localizing antifungal drugs to the correct organelle can markedly enhance their efficacy. *Angew. Chem.* **57**, 6230–6235 (2018).
 91. Campbell, K., Herrera-Dominguez, L., Correia-Melo, C., Zelezniak, A. & Ralser, M. Biochemical principles enabling metabolic cooperativity and phenotypic heterogeneity at the single cell level. *Curr. Opin. Syst. Biol.* **8**, 97–108 (2018).
 92. Franzmann, T. M. & Alberti, S. Protein phase separation as a stress survival strategy. *CSH Perspect. Biol.* **11**, a034058 (2019).
 93. Delarue, M. et al. mTORC1 controls phase separation and the biophysical properties of the cytoplasm by tuning crowding. *Cell* **174**, 338–349.e20 (2018).
 94. Roemer, T. & Krysan, D. J. Antifungal drug development: challenges, unmet clinical needs, and new approaches. *Cold Spring Harb. Perspect. Med.* **4**, a019703 (2014).
 95. Cornet, M. et al. Deletions of endocytic components VPS28 and VPS32 affect growth at alkaline pH and virulence through both RIM101-dependent and RIM101-independent pathways in *Candida albicans*. *Infect. Immun.* **73**, 7977–7987 (2005).
 96. Gerstein, A. C., Rosenberg, A., Hecht, I. & Berman, J. diskImageR: quantification of resistance and tolerance to antimicrobial drugs using disk diffusion assays. *Microbiology* **162**, 1059–1068 (2016).
 97. Ben-Ami, R. et al. Heteroresistance to fluconazole is a continuously distributed phenotype among *Candida glabrata* clinical strains associated with in vivo persistence. *mBio* **7**, e00655–16 (2016).
 98. Sionov, E., Chang, Y. C., Garraffo, H. M. & Kwon-Chung, K. J. Heteroresistance to fluconazole in *Cryptococcus neoformans* is intrinsic and associated with virulence. *Antimicrob. Agents Chemother.* **53**, 2804–2815 (2009).
 99. Varma, A. & Kwon-Chung, K. J. Heteroresistance of *Cryptococcus gattii* to fluconazole. *Antimicrob. Agents Chemother.* **54**, 2303–2311 (2010).
 100. Sionov, E., Chang, Y. C. & Kwon-Chung, K. J. Azole heteroresistance in *Cryptococcus neoformans*: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment. *Antimicrob. Agents Chemother.* **57**, 5127–5130 (2013).
 101. Stone, N. R. et al. Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. *J. Clin. Invest.* **129**, 999–1014 (2019).
This study tracks series of clinical *Cryptococcus neoformans* isolates from individual patients with HIV from Tanzania and finds that heteroresistance is quite common and is often, but not always, associated with specific chromosomal aneuploidies.
 102. Desai, J. V., Mitchell, A. P. & Andes, D. R. Fungal biofilms, drug resistance, and recurrent infection. *Cold Spring Harb. Perspect. Med.* **4**, a019729 (2014).
 103. Lohse, M. B., Gulati, M., Johnson, A. D. & Nobile, C. J. Development and regulation of single- and multi-species *Candida albicans* biofilms. *Nat. Rev. Microbiol.* **16**, 19–31 (2018).
 104. Ramage, G., Vande Walle, K., Wickes, B. L. & Lopez-Ribot, J. L. Standardized method for in vitro antifungal susceptibility testing of *Candida albicans* biofilms. *Antimicrob. Agents Chemother.* **45**, 2475–2479 (2001).
 105. Taff, H. T. et al. A *Candida* biofilm-induced pathway for matrix glucan delivery: implications for drug resistance. *PLoS Pathog.* **8**, e1002848 (2012).
 106. Li, P., Seneviratne, C. J., Alpi, E., Vizzaino, J. A. & Jin, L. Delicate metabolic control and coordinated stress response critically determine antifungal tolerance of *Candida albicans* biofilm persisters. *Antimicrob. Agents Chemother.* **59**, 6101–6112 (2015).
 107. Denega, I., d'Enfert, C. & Bachellier-Bassi, S. *Candida albicans* biofilms are generally devoid of persister cells. *Antimicrob. Agents Chemother.* **63**, e01979–18 (2019).
 108. Al-Daheri, R. S. & Douglas, L. J. Absence of amphoterin B-tolerant persister cells in biofilms of some *Candida* species. *Antimicrob. Agents Chemother.* **52**, 1884–1887 (2008).
 109. Stevens, D. A., Espiritu, M. & Parmar, R. Paradoxical effect of caspofungin: reduced activity against *Candida albicans* at high drug concentrations. *Antimicrob. Agents Chemother.* **48**, 3407–3411 (2004).
 110. Stevens, D. A., White, T. C., Perlin, D. S. & Selltreinnikoff, C. P. Studies of the paradoxical effect of caspofungin at high drug concentrations. *Diagn. Microbiol. Infect. Dis.* **51**, 173–178 (2005).
 111. Rueda, C., Cuenca-Estrella, M. & Zaragoza, O. Paradoxical growth of *Candida albicans* in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence. *Antimicrob. Agents Chemother.* **58**, 1071–1083 (2014).
This study presents a detailed assessment of the cellular changes that accompany growth beyond the MIC in caspofungin as well as the effects that those changes have on fitness in mammalian hosts.
 112. Wagener, J. & Loiko, V. Recent insights into the paradoxical effect of echinocandins. *J. Fungi* **4**, 5 (2017).
 113. Rueda, C. et al. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia. *Clin. Microbiol. Infect.* **23**, 49.e1–49.e8 (2017).
 114. Lee, M. K. et al. Susceptibility and trailing growth of *Candida albicans* to fluconazole: results of a Korean multicentre study. *Mycoses* **50**, 148–149 (2007).
 115. Arthington-Skaggs, B. A. et al. Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing *Candida* isolates. *Antimicrob. Agents Chemother.* **46**, 2477–2481 (2002).
 116. Rex, J. H. et al. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. *Antimicrob. Agents Chemother.* **42**, 129–134 (1998).
 117. Colombo, A. L. et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. *Intensive Care Med.* **40**, 1489–1498 (2014).
 118. Hirakawa, M. P. et al. Genetic and phenotypic intra-species variation in *Candida albicans*. *Genome Res.* **25**, 413–425 (2015).
 119. Huang, M. Y., Woolford, C. A., May, G., McManus, C. J. & Mitchell, A. P. Circuit diversification in a biofilm regulatory network (vol 15, e1007787, 2019). *PLoS Pathog.* **15**, e1007787 (2019).
 120. Hooper, R. W., Ashcraft, D. S. & Pankey, G. A. In vitro synergy with fluconazole plus doxycycline or tigecycline against clinical *Candida glabrata* isolates. *Med. Mycol.* **57**, 122–126 (2019).
 121. Lu, M. et al. Linezolid in combination with azoles induced synergistic effects against *Candida albicans* and protected *Galleria mellonella* against experimental candidiasis. *Front. Microbiol.* **9**, 3142 (2018).
 122. da Silva, C. R. et al. Synergistic effects of amiodarone and fluconazole on *Candida tropicalis* resistant to fluconazole. *Antimicrob. Agents Chemother.* **57**, 1691–1700 (2013).
 123. Li, H. et al. Resistance reversal induced by a combination of fluconazole and tacrolimus (FK506) in *Candida glabrata*. *J. Med. Microbiol.* **64**, 44–52 (2015).
 124. Gu, W., Guo, D., Zhang, L., Xu, D. & Sun, S. The synergistic effect of azoles and fluoxetine against resistant *Candida albicans* strains is attributed to attenuating fungal virulence. *Antimicrob. Agents Chemother.* **60**, 6179–6188 (2016).
 125. Costa-de-Oliveira, S. et al. Ibusprofen potentiates the in vivo antifungal activity of fluconazole against *Candida albicans* murine infection. *Antimicrob. Agents Chemother.* **59**, 4289–4292 (2015).
 126. Uppuluri, P., Nett, J., Heitman, J. & Andes, D. Synergistic effect of calcineurin inhibitors and fluconazole against *Candida albicans* biofilms. *Antimicrob. Agents Chemother.* **52**, 1127–1132 (2008).
 127. Yu, S. J., Chang, Y. L. & Chen, Y. L. Calcineurin signaling: lessons from *Candida* species. *FEMS Yeast Res.* **15**, fov016 (2015).
 128. Hubbard, M., Bradley, M., Sullivan, P., Shepherd, M. & Forrester, I. Evidence for the occurrence of calmodulin in the yeasts *Candida albicans* and *Saccharomyces cerevisiae*. *FEBS Lett.* **137**, 85–88 (1982).
 129. O'Meara, T. R., Robbins, N. & Cowen, L. E. The Hsp90 chaperone network modulates *Candida* virulence traits. *Trends Microbiol.* **25**, 809–819 (2017).

Acknowledgements

The authors thank M. Ralser, D. Jarosz and members of the Berman laboratory for helpful comments, and S. Everson, Iuliana Ene, Brown University, Anton Levitan, Tel-Aviv University, Alecia C. Gerstein, University of Manitoba and M. Hajooj for help with illustrations. Work in the authors' laboratories was supported by the European Research Council (RAPLODAPT 340087) and the Israel Science Foundation (grant number 997/18) (J.B.), and by the National Institutes of Health (1R01AI125094) (D.J.K.).

Author contributions

Both authors contributed to all aspects of the article.

Competing interests

The authors declare no competing interests.

Peer review information

Nature Reviews Microbiology thanks J. Morschhauser, D. Perlin and D. Sanglard for their contribution to the peer review of this work.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41579-019-0322-2>.

RELATED LINKS

Candida Genome Database: <http://www.candidagenome.org/>